Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)
Condition(s):Biliary Tract Cancer; Gemox ChemotherapyLast Updated:March 20, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Biliary Tract Cancer; Gemox ChemotherapyLast Updated:March 20, 2024Recruiting
Condition(s):Chronic Myeloid LeukemiaLast Updated:December 11, 2023Active, not recruiting
Condition(s):MSS; pMMR; Metastatic Colorectal AdenocarcinomaLast Updated:October 5, 2021Unknown status
Condition(s):Advanced EGFR-TKI-resistant Non-Small Cell Lung CancerLast Updated:June 28, 2016Unknown status
Condition(s):MMR on 12 MonthLast Updated:September 5, 2021Unknown status
Condition(s):NSCLC; Apatinib; EGFR-TKILast Updated:April 4, 2019Unknown status
Condition(s):Non-proliferative Diabetic RetinopathyLast Updated:December 8, 2023Active, not recruiting
Condition(s):Hormone Refractory Prostate CancerLast Updated:February 18, 2021Completed
Condition(s):Non Small Cell Lung CancerLast Updated:March 12, 2024Not yet recruiting
Condition(s):First or Second Recurrence of GlioblastomaLast Updated:April 19, 2016Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.